|Dr. Dolores J. Schendel||Chief Scientific Officer, Member of Exec. Management Board and Head of R&D||375k||N/A||N/A|
|Dr. Selwyn Ho MB BS, MBBS||CEO & Member of Exec. Management Board||N/A||N/A||1971|
|Dr. Ernst-Ludwig Winnacker||Co-Founder & Chairman Scientific Advisory Board||N/A||N/A||1941|
|Dr. Birger Kohlert||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Anna Niedl||VP Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Dr. Rene Goedkoop||Acting Chief Medical Officer||N/A||N/A||N/A|
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies with a focus on T cell receptor-modified T cells in the areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indications. Medigene AG has a strategic partnership with 2seventy bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.
Medigene AG’s ISS governance QualityScore as of 1 October 2022 is 3. The pillar scores are Audit: 7; Board: 3; Shareholder rights: 1; Compensation: 3.